Enochian Biosciences receives non-compliance letter from Nasdaq

Stock Information for Enochian Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enochian Biosciences Inc.

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
Grabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)
Grabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)
Enochian BioSciences' CEO Letter to Shareholders
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.